Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
1.5 Fte (12)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
The Health Policy Partnership (HPP)
EU Transparency Register
223430420230-66 First registered on 08 Jan 2016
Goals / Remit
We are a specialist health policy consultancy. We create innovative policy initiatives and powerful evidence–based communications for organisations across the health spectrum. We provide a unique, seamless approach to help resolve the most complex issues facing our health care systems. We do this through rigorous research and expert synthesis of evidence, inter-sectoral collaboration, and powerful communications that act as the starting point for meaningful changes in policy and practice.
Main EU files targeted
Public health and healthcare policy, specific focus in cardiovascular disease, cancer, heart failure and rare diseases.
Address
Head Office
The Health Policy Partnership 68-69 St Martin's Lane
London WC2N 4JS
UNITED KINGDOMEU Office
The Health Policy Partnership 68-69 St Martin's Lane
London WC2N 4JS
UNITED KINGDOMWebsite
-
People
Total lobbyists declared
12
Employment time Lobbyists 25% 2 10% 10 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Time provided above relates to HPP staff time dedicated to any formal engagement with MEPs, EU officials, or where there is policy activity directly involving or targeting EU institutions - i.e. it excludes general health policy activities where other audiences are our primary targets (e.g. national policy makers, academic experts, clinicians, health providers etc), and global activities.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Professional consultancies
-
Networking
Affiliation
Heart Failure Policy Network - www.hfpolicynetwork.eu
(provide secretariat and lead project)Member organisations
Please see www.hfpolicynetwork.eu
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
100,000€ - 199,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
HEART FAILURE POLICY NETWORK (HFPN)
HPP acts as Secretariat for the HF Policy Network, a multidisciplinary group of experts from across Europe working with patients, health professionals and other stakeholders to lead significant policy changes that may improve the lives of people with heart failure (HF). The HFPN has ongoing relationships with several MEPs who donate their time for free to support (and act as Members of) the HFPN. HFPN held its Heart Failure Policy Summit, a virtual online event, in October-November 2022. The 2022 Summit provided a much-needed forum for collaboration and discussion between patient advocates from different sectors. The Summit aimed to elevate the efforts of national-level heart failure advocates to engage decision-makers and policymakers across Europe. Several MEPs addressed the event. The Taoiseach Michéal Martin provided a pre-recorded presentation.
THE LUNG CANCER POLICY NETWORK (LCPN)
HPP acts as Secretariat for the LCPN which was launched in 2021 as an initiative of the Lung Ambition Alliance. It is a global network of multidisciplinary experts from across the lung cancer community, which includes clinicians, researchers, patient organisations and industry partners. The Network aims to improve lung cancer survival worldwide. LCPN works by engaging policymakers – sharing research, reports and recommendations that highlight opportunities to diagnose and treat lung cancer earlier. LCPN hopes to make lung cancer an international policy priority, and by doing so, improve the quality of life for people diagnosed with lung cancer and to reduce the number of deaths caused by the condition. The LCPN submitted proposed amendments to the EU Commission draft recommendation on cancer screening. It also submitted a response to the EU call for evidence on cancer screening. In addition, the LCPN organised two virtual events, inviting interested MEPs.
THOUGHT LEADERSHIP FORUM ON CARDIOVASCULAR DISEASE
HPP initiated the Thought Leadership Forum on Cardiovascular Disease in 2022. The project is advised by a multidisciplinary group of senior stakeholders seeking to ignite greater political urgency in CVD. It was established to stimulate new strategic debates in CVD to ultimately accelerate policy leadership and health system transformation in the societal interest. The Forum organised a webinar in November 2022, on ‘a new future for cardiovascular health: how do we unite decision-makers behind the next generation of national CVD plans?’. Inviting MEPs interested in the topic.
WILSON'S DISEASE POLICY NETWORK
HPP runs the Secretariat for the Wilson’s Disease Policy Network, in collaboration with its multi-stakeholder Steering Committee. All outputs are non-promotional, evidence based and shaped by the Steering Committee, which has editorial control. In 2023, HPP is planning to hold an event at the European Parliament, with patient advocates, physicians and policy experts in the field of rare diseases to discuss what more can be done at an EU level to drive change. Preparations for this event, including contacting interested MEPs, began in late 2022.Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 25 Oct 2023 Location Brussels, Belgium Subject Role of the EU in promoting heart health Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Katherine Power (Cabinet member)